Ichnos Glenmark Innovation to present updated ISB 2001 Phase 1 data at 68th ASH Annual Meeting
Ichnos Glenmark Innovation will present updated Phase 1 data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma in an oral session at the 68th ASH Annual Meeting on December 12, 2026.
By ScoutQuest · · 1 min read
- Conference / Presentation Date
- 68th ASH Annual Meeting on December 12, 2026, oral session
- Drug Candidate
- ISB 2001 (ABBV-2001), CD38 x BCMA x CD3 trispecific T-cell engager
- Study / Partnership
- Phase 1 TRIgnite-1 study; Phase 1/2 combination study; AbbVie licensing agreement July 2025
- Release
- Press release
🏭 Updated data from the Phase 1 TRIgnite-1 study include longer follow-up from the dose-escalation phase and early results from dose-expansion cohorts in patients with heavily pretreated multiple myeloma.
📌 ISB 2001 (ABBV-2001) is an investigational first- and only-in-class CD38 x BCMA x CD3 trispecific T-cell engager being evaluated in multiple myeloma through the Phase 1 TRIgnite-1 study and a Phase 1/2 combination study.
📌 IGI President and CEO Lida Pacaud, M.D. said the results represent an important milestone, and that IGI remains focused with partner AbbVie on advancing ISB 2001 (ABBV-2001) as a potential new treatment option for relapsed/refractory multiple myeloma.
📌 IGI and AbbVie formed an exclusive global licensing agreement for the trispecific ISB 2001 (ABBV-2001) in July 2025.
Also from Glenmark Pharmaceuticals
Glenmark Pharmaceuticals sets Q2 FY2027 earnings call for Nov 6, 2026, 8:30–9:30 am IST
23 Oct 2026
Board meeting on November 5 to consider and approve September quarter unaudited results
23 Oct 2026
Nomura retained buy call on Glenmark Pharma with stock up about 4.8%, raising target price to 3,750 rupees from 3,300 rupees
7 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.